Overview

2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy

Status:
Active, not recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
Second-line therapy with Nal-IRI after failure gemcitabine/nab-paclitaxel in advanced pancreatic cancer - predictive role of 1st-line therapy
Phase:
Phase 3
Details
Lead Sponsor:
AIO-Studien-gGmbH
Collaborators:
Baxalta now part of Shire
Crolll Gmbh
Servier Deutschland GmbH
Treatments:
Albumin-Bound Paclitaxel
Gemcitabine
Irinotecan
Paclitaxel